The little-known link between climate change and brain health
PARIS : The link between brain health and climate disruption was recently highlighted in a 16-minute mini-documentary shared online last month by FutureNeuro @ the Research Ireland Centre for Translational Brain Science, based in the RCSI University of Medicine and Health Sciences.
Produced in partnership with the International League Against Epilepsy (ILAE), the film explains that over three billion people worldwide are living with neurological disorders.
Research has already established a link between rising temperatures and an exacerbation of the symptoms of certain neurological diseases sensitive to temperature variations.
This is the case, for example, with Dravet syndrome, a rare and severe form of childhood epilepsy, in which a sudden rise in temperature is likely to lead to more frequent seizures, as well as altered brain function.
Professor Sanjay Sisodiya, chair of the ILAE Climate Change Commission, explained: 'The brain is key to our response to challenges from our surroundings, and many parts of the brain are sensitive to the temperature at which they have to work.
'As a result, if the brain is already affected by disease, it may be more vulnerable to the challenges posed by the effects of climate change.
'As climate change continues to worsen, it is essential that we pay attention to its effects on people with neurological conditions all around the world.'
The professor of neurology at University College London is also the author of a study published in 2024 in The Lancet Neurology, which shows that extreme temperatures – whether low or high – are likely to exacerbate disorders linked to 19 neurological diseases, including dementia, epilepsy and migraine.
AI tools to identify at-risk populations
Through patient testimonials, the documentary highlights the difficulties people with neurological pathologies can encounter on a daily basis, such as the inability to leave the house in the event of a heatwave and the social isolation that can ensue.
Extreme temperatures can also disrupt medical supply chains, damaging cold-stored medicines and hindering access to healthcare.
As ILAE president J Helen Cross notes: 'Climate change is one of the most pressing global health challenges of our time, and its impact on people with epilepsy and other neurological conditions is becoming increasingly clear.
'This film is a powerful step towards placing neurological health firmly within the climate conversation.'
Beyond its primary aim of raising awareness for a phenomenon of which many people are still largely unaware, the documentary aims to encourage the funding and development of more advanced scientific research on the subject.
One way to better understand the link between brain health and rising temperatures linked to climate change is to capitalise on imaging and genetic technologies, including AI-driven predictive models to identify at-risk populations and develop targeted interventions.
'New imaging and genetic technologies allow us to learn more about the brain's temperature control systems, and how this is altered in conditions such as epilepsy,' said FutureNeuro director David Henshall, a professor of molecular physiology and neuroscience at RCSI.
'Understanding these mechanisms could open the door to new treatments or preventative strategies, helping to reduce the impact of heat on seizure risk.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 days ago
- Malay Mail
AstraZeneca beats Q2 forecasts on booming US drug sales, eyes US$80b revenue by 2030
LONDON, July 29 — AstraZeneca Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the US, where it has invested US$50 billion (RM212 billion) to expand amid tariff threats from Washington. The performance is a boost for the UK's largest-listed company by market value as the wider sector braces for US tariffs on pharmaceutical imports and navigates pressure after President Donald Trump's order pushing for drugmakers to cut US prices to what other countries pay. AstraZeneca shares rose as much as 2.2 per cent by 0813 GMT. The drugmaker in April forecast only a limited impact from potential US tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-US trade deal over the weekend will result in a 15 per cent tariff on pharmaceuticals from the region. The US accounted for more than 40 per cent of AstraZeneca's revenue in 2024. The company had prioritised the market — the world's largest, worth US$635 billion — even before Trump's return to office. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its US expansion to reach US$80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3 per cent. 'Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent,' CEO Pascal Soriot said. Cancer drugs outperform Sales of oncology drugs, constituting nearly half of AstraZeneca's revenue, were up 18 per cent at US$6.31 billion at constant currency rates in the quarter. Jefferies analysts said sales of drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Total revenue for the three months ended June grew 11 per cent to US$14.46 billion, with double-digit growth in the US despite headwinds from changes in US Medicare price negotiations. Core earnings stood at US$2.17 per share. That compares with analysts' expectations of US$2.16, and US$14.15 billion in sales, according to a company-provided consensus. 'Operationally, this is the type of quarter we want to see,' Barclays analysts said. AstraZeneca is also hoping to move on from scandals in its second-biggest market, China, where it this year faced minor fines related to cancer drugs. It is also fighting patent challenges from an individual against Tagrisso. The company also delayed late-stage Avanzar trial data for a key lung cancer treatment to the first half of 2026. — Reuters
Malay Mail
3 days ago
- Malay Mail
Global liver cancer cases set to nearly double by 2050 without action, study warns
PARIS, July 29 — The number of people with liver cancer will nearly double worldwide by 2050 unless more is done to address preventable causes such as obesity, alcohol consumption and hepatitis, a study warned today. New cases of liver cancer—the sixth most common form of the disease—will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal. It is also the third deadliest of all cancers, with the study predicting it would take 1.37 million lives by the middle of the century. However three out of five cases of liver cancer could be prevented, the international team of experts said. The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called MASLD, which was previously known as non-alcoholic fatty liver disease. The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 percent of all cases of liver cancer by 2050, up more than two percentage points from 2022. Cancer due to obesity-linked fat in livers will rise to 11 percent, also up more than two percentage points, the researchers calculated. The large-scale study, which reviewed the available evidence on the subject, underscored 'the urgent need for global action' on liver cancer, the authors said. The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people with obesity or diabetes about fatty-liver disease in the United States, Europe and Asia.— AFP
Free Malaysia Today
3 days ago
- Free Malaysia Today
7,000 steps ‘enough to significantly boost health'
Walking 7,000 steps a day is linked to 38% reduction in risk of dementia, depression (22%) and diabetes (14%), as well as lower rates of cancer and falls. (Envato Elements pic) PARIS : People who walk 7,000 steps a day have a dramatically lower risk of a broad range of serious health problems, according to the largest review of evidence yet. The most widely promoted target for people tracking their number of steps is 10,000 – but that figure reportedly originally came from a 1960s marketing campaign for a Japanese paedometer. To find a more scientific target, an international team of researchers sifted through 57 previous studies that covered 160,000 people. The results, published in Lancet Public Health, found that walking 7,000 steps a day nearly halved people's risk of early death from all causes, compared to 2,000 steps. The study also looked into health problems not previously covered by research into step counts. Walking 7,000 steps a day was linked to dementia risk falling by 38%, depression by 22%, and diabetes by 14%. It was also associated with lower rates of cancer and falls, though the researchers warned this was based on less evidence. 'You don't need to hit 10,000 steps a day to get major health benefits,' Paddy Dempsey, a study co-author and medical researcher at Cambridge University, told AFP. 'The biggest gains happen before 7,000 steps, and then benefits tend to level off.' While people's speeds vary widely, 7,000 steps adds up to roughly an hour of walking throughout the day. Dempsey emphasised that people already managing 10,000 or more steps should keep it up. But he had a message for people who might find 7,000 steps daunting: 'Don't be discouraged.' 'If you're only getting 2,000-3,000 steps a day, aim to add an extra 1,000 steps. That's just 10-15 minutes of light walking spread across the day,' he advised. Andrew Scott, a researcher at the University of Portsmouth not involved in the study, said 'it demonstrates that overall, more is always better'. 'People should not focus too much on the numbers, particularly on days where activity is limited,' he added. The World Health Organization recommends at least 150 minutes of moderate to intense physical activity a week. Nearly a third of people worldwide do not reach this target, according to WHO.
